306 related articles for article (PubMed ID: 37331504)
1. Xanthine oxidase/NADPH oxidase inhibition by hydralazine attenuates acute kidney injury and prevents the transition of acute kidney injury to chronic kidney disease.
Chiang CH; Chen C; Fang SY; Lin SC; Chen JW; Chang TT
Life Sci; 2023 Aug; 327():121863. PubMed ID: 37331504
[TBL] [Abstract][Full Text] [Related]
2. Antioxidation and Nrf2-mediated heme oxygenase-1 activation contribute to renal protective effects of hydralazine in diabetic nephropathy.
Chang TT; Chiang CH; Chen C; Lin SC; Lee HJ; Chen JW
Biomed Pharmacother; 2022 Jul; 151():113139. PubMed ID: 35623171
[TBL] [Abstract][Full Text] [Related]
3. Low-dose hydralazine prevents fibrosis in a murine model of acute kidney injury-to-chronic kidney disease progression.
Tampe B; Steinle U; Tampe D; Carstens JL; Korsten P; Zeisberg EM; Müller GA; Kalluri R; Zeisberg M
Kidney Int; 2017 Jan; 91(1):157-176. PubMed ID: 27692563
[TBL] [Abstract][Full Text] [Related]
4. Antibiotic-induced intestinal microbiota depletion can attenuate the acute kidney injury to chronic kidney disease transition via NADPH oxidase 2 and trimethylamine-N-oxide inhibition.
Lee J; Lee J; Kim K; Lee J; Jung Y; Hyeon JS; Seo A; Jin W; Weon B; Shin N; Kim S; Lim CS; Kim YS; Lee JP; Hwang GS; Yang SH
Kidney Int; 2024 Jun; 105(6):1239-1253. PubMed ID: 38431216
[TBL] [Abstract][Full Text] [Related]
5. A short treatment with resveratrol after a renal ischaemia-reperfusion injury prevents maladaptive repair and long-term chronic kidney disease in rats.
Martínez-Rojas MÁ; Balcázar H; Ponce-Nava MS; González-Soria I; Marquina-Castillo B; Pérez-Villalva R; Bobadilla NA
J Physiol; 2024 Apr; 602(8):1835-1852. PubMed ID: 38529522
[TBL] [Abstract][Full Text] [Related]
6. Blockade of STAT3 signaling alleviates the progression of acute kidney injury to chronic kidney disease through antiapoptosis.
Park JY; Yoo KD; Bae E; Kim KH; Lee JW; Shin SJ; Lee JS; Kim YS; Yang SH
Am J Physiol Renal Physiol; 2022 May; 322(5):F553-F572. PubMed ID: 35311382
[TBL] [Abstract][Full Text] [Related]
7. NFAT inhibitor 11R-VIVIT ameliorates mouse renal fibrosis after ischemia-reperfusion-induced acute kidney injury.
Xie ZY; Dong W; Zhang L; Wang MJ; Xiao ZM; Zhang YH; Shi WX; Huang Y; Yang Y; Li CL; Fu L; Zhao XC; Li RZ; Li ZL; Chen YH; Ye ZM; Liu SX; Dong Z; Liang XL
Acta Pharmacol Sin; 2022 Aug; 43(8):2081-2093. PubMed ID: 34937917
[TBL] [Abstract][Full Text] [Related]
8. Hyperbaric oxygen preconditioning and the role of NADPH oxidase inhibition in postischemic acute kidney injury induced in spontaneously hypertensive rats.
Kovacevic S; Ivanov M; Miloradovic Z; Brkic P; Vajic UJ; Zivotic M; Mihailovic-Stanojevic N; Jovovic D; Karanovic D; Jeremic R; Nesovic-Ostojic J
PLoS One; 2020; 15(1):e0226974. PubMed ID: 31914135
[TBL] [Abstract][Full Text] [Related]
9. Tubular Elabela-APJ axis attenuates ischemia-reperfusion induced acute kidney injury and the following AKI-CKD transition by protecting renal microcirculation.
Xiong M; Chen H; Fan Y; Jin M; Yang D; Chen Y; Zhang Y; Petersen RB; Su H; Peng A; Wang C; Zheng L; Huang K
Theranostics; 2023; 13(10):3387-3401. PubMed ID: 37351176
[No Abstract] [Full Text] [Related]
10. Hydralazine improves ischemia-induced neovasculogenesis via xanthine-oxidase inhibition in chronic renal insufficiency.
Chang TT; Chen JW
Pharmacol Res; 2020 Jan; 151():104509. PubMed ID: 31678640
[TBL] [Abstract][Full Text] [Related]
11. Divergent effects of AKI to CKD models on inflammation and fibrosis.
Black LM; Lever JM; Traylor AM; Chen B; Yang Z; Esman SK; Jiang Y; Cutter GR; Boddu R; George JF; Agarwal A
Am J Physiol Renal Physiol; 2018 Oct; 315(4):F1107-F1118. PubMed ID: 29897282
[TBL] [Abstract][Full Text] [Related]
12. Cellular communication network factor 2 (CCN2) promotes the progression of acute kidney injury to chronic kidney disease.
Inoue T; Kusano T; Amano H; Nakamoto H; Okada H
Biochem Biophys Res Commun; 2019 Sep; 517(1):96-102. PubMed ID: 31320136
[TBL] [Abstract][Full Text] [Related]
13. A two-stage bilateral ischemia-reperfusion injury-induced AKI to CKD transition model in mice.
Zhang J; Wang X; Wei J; Wang L; Jiang S; Xu L; Qu L; Yang K; Fu L; Buggs J; Cheng F; Liu R
Am J Physiol Renal Physiol; 2020 Aug; 319(2):F304-F311. PubMed ID: 32567350
[TBL] [Abstract][Full Text] [Related]
14. Knockout of Zeb2 ameliorates progression of renal tubulointerstitial fibrosis in a mouse model of renal ischemia-reperfusion injury.
Inotani S; Taniguchi Y; Nakamura K; Nishikawa H; Matsumoto T; Horino T; Fujimoto S; Sano S; Yanagita M; Terada Y
Nephrol Dial Transplant; 2022 Feb; 37(3):454-468. PubMed ID: 34724064
[TBL] [Abstract][Full Text] [Related]
15. TNF or EGFR inhibition equally block AKI-to-CKD transition: opportunities for etanercept treatment.
Abdelmageed MM; Kefaloyianni E; Arthanarisami A; Komaru Y; Atkinson JJ; Herrlich A
Nephrol Dial Transplant; 2023 May; 38(5):1139-1150. PubMed ID: 36269313
[TBL] [Abstract][Full Text] [Related]
16. cMet agonistic antibody prevents acute kidney injury to chronic kidney disease transition by suppressing Smurf1 and activating Smad7.
Li L; Lee J; Cho A; Kim JH; Ju W; An JN; Park JH; Zhu SM; Lee J; Yu SS; Lim CS; Kim DK; Kim YS; Yang SH; Lee JP
Clin Sci (Lond); 2021 Jun; 135(11):1427-1444. PubMed ID: 34061176
[TBL] [Abstract][Full Text] [Related]
17. Role of protease-activated receptor 4 in mouse models of acute and chronic kidney injury.
Erreger K; Cao S; Pan Y; Jiang M; Zhang MZ; Harris RC; Hamm HE
Am J Physiol Renal Physiol; 2024 Feb; 326(2):F219-F226. PubMed ID: 38031732
[TBL] [Abstract][Full Text] [Related]
18. A single administration of FGF2 after renal ischemia-reperfusion injury alleviates post-injury interstitial fibrosis.
Tan X; Tao Q; Yin S; Fu G; Wang C; Xiang F; Hu H; Zhang S; Wang Z; Li D
Nephrol Dial Transplant; 2023 Oct; 38(11):2537-2549. PubMed ID: 37243325
[TBL] [Abstract][Full Text] [Related]
19. A bioinspired carbon monoxide delivery system prevents acute kidney injury and the progression to chronic kidney disease.
Nagasaki T; Maeda H; Taguchi K; Yanagisawa H; Nishida K; Kobayashi K; Wada N; Noguchi I; Murata R; Sakai H; Kitagishi H; Saruwatari J; Watanabe H; Otagiri M; Maruyama T
Redox Biol; 2022 Aug; 54():102371. PubMed ID: 35763935
[TBL] [Abstract][Full Text] [Related]
20. Tubulovascular protection from protease-activated receptor-1 depletion during AKI-to-CKD transition.
Lok SWY; Yiu WH; Zou Y; Xue R; Li H; Ma J; Chen J; Chan LYY; Lai KN; Tang SCW
Nephrol Dial Transplant; 2023 Sep; 38(10):2232-2247. PubMed ID: 36914214
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
